<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24608864</article-id><article-id pub-id-type="pmc">3946627</article-id><article-id pub-id-type="publisher-id">PONE-D-13-37972</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0090828</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Computer Science</subject><subj-group><subject>Computer Applications</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Engineering</subject><subj-group><subject>Human Factors Engineering</subject><subj-group><subject>Man Computer Interface</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Immune Suppression</subject></subj-group></subj-group><subj-group><subject>Immunologic Subspecialties</subject><subj-group><subject>Transplantation</subject></subj-group></subj-group></subj-group><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Critical Care and Emergency Medicine</subject><subj-group><subject>Perioperative Critical Care</subject></subj-group></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Adverse Reactions</subject><subject>Clinical Pharmacology</subject><subject>Drug Information</subject><subject>Medical Devices</subject></subj-group></subj-group><subj-group><subject>Non-Clinical Medicine</subject><subj-group><subject>Health Care Policy</subject><subj-group><subject>Health Education and Awareness</subject></subj-group></subj-group><subj-group><subject>Health Care Providers</subject><subj-group><subject>Nurses</subject></subj-group></subj-group><subj-group><subject>Communication in Health Care</subject><subject>Health Informatics</subject><subject>Health Services Administration and Management</subject><subject>Medical Communication</subject><subject>Medical Education</subject><subject>Patient Advocacy</subject></subj-group></subj-group><subj-group><subject>Nursing Science</subject></subj-group><subj-group><subject>Pulmonology</subject></subj-group><subj-group><subject>Surgery</subject><subj-group><subject>Transplant Surgery</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Conventional vs. Tablet Computer-Based Patient Education following Lung Transplantation &#x02013; A Randomized Controlled Trial</article-title><alt-title alt-title-type="running-head">E-Education to Improve Immunosuppressive Adherence</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Suhling</surname><given-names>Hendrik</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rademacher</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zinowsky</surname><given-names>Imke</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fuge</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Greer</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Warnecke</surname><given-names>Gregor</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Smits</surname><given-names>Jacqueline M.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bertram</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Haverich</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Welte</surname><given-names>Tobias</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gottlieb</surname><given-names>Jens</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Dept. of Respiratory Medicine, Hannover Medical School, Hannover, Germany</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Dept. of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Eurotransplant International Foundation, Leiden, The Netherlands</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Dept. of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gregson</surname><given-names>Aric</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of California Los Angeles, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>suhling.hendrik@mh-hannover.de</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: HS JF TW JG. Performed the experiments: HS JR IZ JF TW JG. Analyzed the data: HS JF JS JG. Contributed reagents/materials/analysis tools: HS MG GW AB AH JG. Wrote the paper: HS JR MG AH TW JG. Designed the software for education: HS JG JF.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>7</day><month>3</month><year>2014</year></pub-date><volume>9</volume><issue>3</issue><elocation-id>e90828</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Suhling et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Suhling et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Accurate immunosuppression is of critical importance in preventing rejection, while avoiding toxicity following lung transplantation. The mainstay immunosuppressants are calcineurin inhibitors, which require regular monitoring due to interactions with other medications and diet. Adherence to immunosuppression and patient knowledge is vital and can be improved through patient education. Education using tablet-computers was investigated.</p></sec><sec><title>Objective</title><p>To compare tablet-PC education and conventional education in improving immunosuppression trough levels in target range 6 months after a single education. Secondary parameters were ratio of immunosuppression level measurements divided by per protocol recommended measurements, time and patient satisfaction regarding education.</p></sec><sec><title>Design</title><p>Single-centre, open labelled randomised controlled trial.</p></sec><sec><title>Participants</title><p>Patients &#x0003e;6 months after lung-transplantation with &#x0003c;50% of calcineurin inhibitor trough levels in target range.</p></sec><sec><title>Intervention</title><p>Tablet-pc education versus personal, nurse-led education.</p></sec><sec><title>Measurements</title><p>Calcineurin inhibitor levels in target range 6 months after education, level variability, interval adherence, knowledge and adherence was studied. As outcome parameter, renal function was measured and adverse events registered.</p></sec><sec><title>Results</title><p>Sixty-four patients were 1:1 randomised for either intervention. Levels of immunosuppression 6 months after education were equal (tablet-PC 58% vs. conventional 48%, p&#x0200a;=&#x0200a;0.27), both groups improved in achieving a CNI trough level within target range by either education method (delta tablet-PC 29% vs. conventional 20%). In all patients, level variability decreased (&#x02212;20.4%), whereas interval adherence remained unchanged. Knowledge about immunosuppression improved by 7% and compliance tests demonstrated universal improvements with no significant difference between groups.</p></sec><sec><title>Conclusion</title><p>Education is a simple, effective tool in improving adherence to immunosuppression. Tablet-PC education was non-inferior to conventional education.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov NCT01398488 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01398488?term=gottlieb+tablet+pc+education&#x00026;rank=1">http://clinicaltrials.gov/ct2/show/NCT01398488?term=gottlieb+tablet+pc+education&#x00026;rank=1</ext-link>.</p></sec></abstract><funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>It has been previously demonstrated in a variety of chronic diseases that non-adherence to medication and other forms of treatment is a major problem <xref rid="pone.0090828-Osterberg1" ref-type="bibr">[1]</xref>, which may impact on long-term outcomes <xref rid="pone.0090828-Trueman1" ref-type="bibr">[2]</xref>, <xref rid="pone.0090828-Ho1" ref-type="bibr">[3]</xref>. Numerous reasons for non-adherence have been reported, including insufficient information, anxiety of side-effects, treatment cost, forgetfulness and lack of perceived benefit <xref rid="pone.0090828-The1" ref-type="bibr">[4]</xref>. Patient education and awareness is considered pivotal in improving adherence, with various concepts having already been developed to address this <xref rid="pone.0090828-Delgado1" ref-type="bibr">[5]</xref>, <xref rid="pone.0090828-DeBleser1" ref-type="bibr">[6]</xref>. Patient educational needs vary greatly depending on their underlying condition, with diseases demanding precise medication dosing (diabetes mellitus) or modifications in health-related behaviour (COPD) appearing to profit most from educational programs <xref rid="pone.0090828-Khunti1" ref-type="bibr">[7]</xref>&#x02013;<xref rid="pone.0090828-Clark1" ref-type="bibr">[10]</xref>.</p><p>Following organ transplantation, patients require highly complex treatment regimes based on various immunosuppressant drugs that have small therapeutic ranges and profound side-effect profiles <xref rid="pone.0090828-Best1" ref-type="bibr">[11]</xref>. Sub-therapeutic immunosuppression remains a leading cause of allograft rejection, graft loss, and death <xref rid="pone.0090828-PollockBarziv1" ref-type="bibr">[12]</xref>. Indirectly it is associated with decreased quality of life and inevitably increased health care costs. Previous studies have demonstrated non-adherence rates in calcineurin inhibitors (CNI) ranging between 13 and 22% <xref rid="pone.0090828-Dew1" ref-type="bibr">[13]</xref>. Non-adherence increases over time after transplantation <xref rid="pone.0090828-Dew1" ref-type="bibr">[13]</xref>, <xref rid="pone.0090828-Dharancy1" ref-type="bibr">[14]</xref>.</p><p>Conventional patient-education requires a trained specialist, a suitable location and is time-intensive <xref rid="pone.0090828-Donaghy1" ref-type="bibr">[15]</xref>. Computer-based patient education has been attempted, with reports suggesting that it can provide a more cost-effective method of educating patients <xref rid="pone.0090828-Miners1" ref-type="bibr">[16]</xref>. Tablet-PCs, with their user-friendly interfaces and large screens improve simplicity and can be handled even by chronically ill or elderly patients. This study investigated whether tablet-PC education could improve immunosuppression adherence amongst lung transplant recipients compared to conventional education strategies.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study design and patient collective</title><p>A prospective randomized open labelled control trial was undertaken at a single university centre (Hannover Medical School, Germany), comparing tablet&#x02013;PC to conventional patient education. Patient recruitment occurred between August 2011 and July 2012. After inclusion, patients first answered a questionnaire assessing their understanding of the various important aspects related to CNI treatment (further described below), before being randomized 1:1 into either of the 2 education groups. At the same visit, patients then participated either in self-directed tablet-PC education or were counselled by a trained nurse (I.Z). Both education content was identical. Six months later they completed the initial questionnaire for a second time.</p><p>Follow-up was 6 months after start of the education (<xref ref-type="fig" rid="pone-0090828-g001">Figure 1</xref>).</p><fig id="pone-0090828-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090828.g001</object-id><label>Figure 1</label><caption><title>Flow chart of inclusion and improvement of immunosuppression.</title><p>Flow chart of inclusion (<bold>A</bold>). Delta % of calcineurin inhibitor trough levels in target range 6 months after patient education compared to 6 months before patient education (<bold>B</bold>). Dashed line marks cut-off of non-inferiority (lower 95% CI of conventional group, p&#x0200a;=&#x0200a;0.17). Visualization of calcineurin inhibitor levels at inclusion (x-axis) and after 6 months (y-axis) (<bold>C</bold>).</p></caption><graphic xlink:href="pone.0090828.g001"/></fig><p>All patients provided written informed consent. The study was approved by the Internal Review Board of the Hannover Medical School (No. 1019&#x02013;2011) and registered under clinicaltrials.gov, No. NCT01398488.</p></sec><sec id="s2b"><title>Inclusion and exclusion criteria</title><p>All patients aged &#x02265;18 years, who had undergone a single, double or heart-lung-transplantation &#x02265;6 months and who regularly participated in our post-transplantation surveillance program were screened for eligibility. Our program provides exclusive centralized monitoring of calcineurin inhibitors (CNI) for all patients at our central lab. Local physicians mail patient blood samples at specified intervals for analysis. To qualify for study participation, patients required a minimum of 10 CNI trough levels in the preceding 6 months, of which less than 50% were in the target range. Patients who were hospitalized during the previous 3 months, who had advanced chronic lung allograft dysfunction (stage 3), chronic kidney disease K/DOQI stage V (eGFR &#x0003c;15 ml/min/1.73 m<sup>2</sup>), oxygen requirement at rest or pulsed steroids in the previous 4 weeks (&#x0003e;500 mg methylprednisolone per day) were excluded. Illiteracy, limited German language skills, need for isolation (multi- or pan-resistant organisms) or other factors limiting patient communication or computer handling were considered additional exclusion criteria.</p></sec><sec id="s2c"><title>Immunosuppression</title><p>Standard maintenance immunosuppression consisted of a triple drug regimen including CNI, prednisolone and mycophenolate mofetil <xref rid="pone.0090828-Gottlieb1" ref-type="bibr">[17]</xref>. Ciclosporine A (CSA) was the 1<sup>st</sup> line CNI, with exception of combined-organ recipients who received tacrolimus. Patients with recurrent or steroid-resistant rejection episodes or CSA intolerance were switched to tacrolimus. Target CSA trough levels, as measured by liquid chromatography were 180 ng/ml (0&#x02013;6 months), 140 ng/ml (6&#x02013;12 months), 100 ng/ml (12&#x02013;24 months) and 60 ng/ml (&#x0003e;24 months). A target range of &#x000b1;20 ng/ml was defined. Target trough levels for tacrolimus were 12 ng/ml (0&#x02013;6 months), 10 ng/ml (6&#x02013;12 months), 8 ng/ml (12&#x02013;24 months) and 6 ng/ml (&#x0003e;24 months). A target range of &#x000b1;2 ng/ml was defined for tacrolimus. Patients demonstrating variable trough levels were required to send control samples every 1&#x02013;2 weeks. Levels out of target range were re-checked after 1 week following dose adjustment. In stable patients, control intervals were gradually lengthened to a maximum of every 4 weeks.</p></sec><sec id="s2d"><title>Intervention: Education materials and education content</title><p>Educational material was devised by lung-transplant specialists (J.G., H.S), and paper- and computer-based presentations of identical content were designed (J.F.). Content differed slightly depending on whether patients were receiving cyclosporine or tacrolimus, necessitating two sets of educational aids. An iPad (Apple Inc., second generation) was used in the tablet-pc group for education. A Keynote presentation (Apple Inc.) consisting of 30 slides and 4 video clips totalling 12:45 min were included. Patients unfamiliar with using an iPad received short instruction before commencing their tutorial. In the conventional group, a trained nurse-specialist (I.Z.) using the designated written material provided patient instruction.</p><p>Educational content comprised of highlighting the importance of regular medication and side-effects (e.g. rejection or infection) and subsequently provided practical tips on how to achieve stable drug levels (<xref ref-type="supplementary-material" rid="pone.0090828.s002">Table S1</xref>). Incorporated video clips emphasized evidence for immunosuppression and the importance of ongoing adherence. This included a patient explaining regular CNI intake, another illustrating correct storage of immunosuppressive drugs and one explaining common causes of variation in drug levels (<xref ref-type="supplementary-material" rid="pone.0090828.s001">Figure S1</xref>).</p><p>All patients received a single page summary sheet to take home and were encouraged to ask further questions during follow-up.</p><p>The iPads were cleaned between patients according to standard recommendations obtained from the deBac-App (available via iTunes, PLRI MedAppLab, Hannover). All software used was regularly updated to latest versions.</p></sec><sec id="s2e"><title>Outcome measurement</title><p>Primary objective was percentage of immunosuppression levels in target range 6 months after education and the comparison between the table-pc and the conventional education group. Secondary objectives were interval adherence, which is defined as the number of measurements in which the target level is reached out of the total number of measurements and time required completing the questionnaire and documentation. The glomerular filtration rate before inclusion and at 6 months was compared and adverse events, hospitalisation, rejection or infection were monitored (<xref ref-type="table" rid="pone-0090828-t001">Table 1</xref>).</p><table-wrap id="pone-0090828-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090828.t001</object-id><label>Table 1</label><caption><title>End points.</title></caption><alternatives><graphic id="pone-0090828-t001-1" xlink:href="pone.0090828.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic><underline>Primary endpoint:</underline></italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Percentage of calcineurin inhibitor trough levels in target range 6 months after patient education</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic><underline>Secondary endpoints:</underline></italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Improvement of percentage of calcineurin inhibitor trough levels in target range (Delta %) of the next 10 measurements after patient education compared to the last 10 measurements before patient education</td></tr><tr><td align="left" rowspan="1" colspan="1">Trough level variability 6 months after patient education compared to 6 months before patient education</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of immunosuppression level measurements vs. recommended measurements</td></tr><tr><td align="left" rowspan="1" colspan="1">Total time of education</td></tr><tr><td align="left" rowspan="1" colspan="1">Total time of answering questionnaire</td></tr><tr><td align="left" rowspan="1" colspan="1">Improvement of patient knowledge on immunosuppressive after patient education</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient satisfaction</td></tr><tr><td align="left" rowspan="1" colspan="1">Self rated adherence to immunosuppressive medication (BAASIS scale)</td></tr><tr><td align="left" rowspan="1" colspan="1">Therapy adherence 6 months after patient education compared to 6 months before patient education</td></tr><tr><td align="left" rowspan="1" colspan="1">Glomerular filtration rate 6 months after patient education compared to baseline</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s2f"><title>Questionnaires for medication intake adherence</title><p>To assess patient medication intake adherence, all participants completed the Basel assessment of adherence with immunosuppressive medication scales (BAASIS) <xref rid="pone.0090828-Walsh1" ref-type="bibr">[18]</xref>&#x02013;<xref rid="pone.0090828-Lennerling1" ref-type="bibr">[20]</xref>, the immunosuppressant therapy adherence barrier instrument (ITBS) <xref rid="pone.0090828-Chisholm1" ref-type="bibr">[21]</xref> and the Morisky Score <xref rid="pone.0090828-Morisky1" ref-type="bibr">[22]</xref>. The BAASIS questionnaire included 4 questions (0&#x02013;4 points) evaluating missed CNI consumption in the last 4 weeks, consecutive occasions were CNI medication was missed, delays of &#x02265;2 hours in CNI consumption and autonomous CNI dose alteration. The Morisky score has been described previously (0&#x02013;4 points) <xref rid="pone.0090828-Morisky1" ref-type="bibr">[22]</xref>. Higher scores in all tests correlated with better adherence. The ITBS examines 13 items using a Likert-type scale (1&#x0200a;=&#x0200a; &#x02018;strongly disagree&#x02019; to 5&#x0200a;=&#x0200a; &#x02018;strongly agree&#x02019;) as previously described <xref rid="pone.0090828-Chisholm1" ref-type="bibr">[21]</xref>.</p></sec><sec id="s2g"><title>Physicians' valuation of adherence</title><p>Physicians independently ranked patient adherence in five categories, including drug levels, physical fitness, communication with the transplantation centre, completion of daily home-spirometry and general health awareness. Good, moderate and bad adherence was differentiated.</p></sec><sec id="s2h"><title>Questions evaluating satisfaction and knowledge</title><p>Questions relating to patient satisfaction regarding educational training and questionnaire satisfaction were also incorporated. Knowledge pertaining to immunosuppressant medication was assessed using 20 yes/no questions derived directly from the educational material. Knowledge was rated to be 0&#x02013;100%.</p><p>The questionnaire was completed either electronically via tablet-PC or in written form and was provided before education and 6 months subsequently.</p></sec><sec id="s2i"><title>Tablet-PC usage and link to local database</title><p>Patients in the tablet-PC group could use an AluPen (Just mobile, Germany) for data entry. Questionnaires were completed using FileMaker Go (v. 11, FileMaker Inc., USA) installed on the iPads, with data being transferred via WiFi in real time to a study database in FileMaker Pro 10 Server hosted on the local intranet.</p></sec><sec id="s2j"><title>Methods against bias</title><p>All patients attending our outpatient clinic were screened for eligibility. Blinding was not undertaken. Randomisation involved an allocation sequence using numbered containers (created by J.F. using <ext-link ext-link-type="uri" xlink:href="http://www.random.org">www.random.org</ext-link>), with patients being assigned to groups based on their inclusion number. Stratification was performed for cystic fibrosis (CF) patients due to comparatively younger age (median 27 years vs. 55 years for other diagnoses) to minimize bias due to better computer literacy among younger patients as well as their increased susceptibility to variable drug absorption that can profoundly influence drug pharmacokinetics, leading to greater fluctuation in trough levels <xref rid="pone.0090828-DelTacca1" ref-type="bibr">[23]</xref>.</p></sec><sec id="s2k"><title>Statistical analysis</title><p>Our calculations indicated that a cohort of 62 patients was required to achieve statistical power of 95% in detecting a 20% difference therapeutic trough-levels between both groups. This estimation of improvement was derived from previous studies. All continuous variables are presented as median with inter-quartile ranges (25% and 75%). Likert-scales with less than 5 points (satisfaction and Morisky Score) were expressed as mean &#x000b1; standard deviation. Variables were compared between the groups using student's t-test (<xref ref-type="table" rid="pone-0090828-t002">Table 2</xref> and <xref ref-type="table" rid="pone-0090828-t003">3</xref> for numeric data) or non-parametric testing (Mann-Whitney U) (<xref ref-type="table" rid="pone-0090828-t004">Table 4</xref>) in cases of non-normal distribution. Categorical variables were compared between the groups using the chi-square test. All reported P values are two-sided and the level of significance was set at p&#x0003c;0.05.</p><table-wrap id="pone-0090828-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090828.t002</object-id><label>Table 2</label><caption><title>Demographics.</title></caption><alternatives><graphic id="pone-0090828-t002-2" xlink:href="pone.0090828.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">Subgroup</td><td align="left" rowspan="1" colspan="1">All patients, n&#x0200a;=&#x0200a;64</td><td align="left" rowspan="1" colspan="1">Tablet-pc group, n&#x0200a;=&#x0200a;32</td><td align="left" rowspan="1" colspan="1">Conventional group, n&#x0200a;=&#x0200a;32</td><td align="left" rowspan="1" colspan="1">Significance</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>FEV1% baseline (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">93 (84; 97)</td><td align="left" rowspan="1" colspan="1">93 (82; 97)</td><td align="left" rowspan="1" colspan="1">93.5 (88.3; 96.8)</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade of chronic rejection (BOS grade)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="left" rowspan="1" colspan="1">52 (82.5)</td><td align="left" rowspan="1" colspan="1">24 (78)</td><td align="left" rowspan="1" colspan="1">28 (88)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="left" rowspan="1" colspan="1">11 (17.5)</td><td align="left" rowspan="1" colspan="1">7 (22)</td><td align="left" rowspan="1" colspan="1">4 (12)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Underlying disease, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Cystic fibrosis</bold>
</td><td align="left" rowspan="1" colspan="1">22 (34)</td><td align="left" rowspan="1" colspan="1">9 (28)</td><td align="left" rowspan="1" colspan="1">13 (41)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Pulmonary fibrosis</bold>
</td><td align="left" rowspan="1" colspan="1">12 (19)</td><td align="left" rowspan="1" colspan="1">7 (22)</td><td align="left" rowspan="1" colspan="1">5 (16)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Emphysema</bold>
</td><td align="left" rowspan="1" colspan="1">5 (8)</td><td align="left" rowspan="1" colspan="1">2 (6)</td><td align="left" rowspan="1" colspan="1">3 (9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Pulm. Hypertension</bold>
</td><td align="left" rowspan="1" colspan="1">7 (11)</td><td align="left" rowspan="1" colspan="1">4 (12)</td><td align="left" rowspan="1" colspan="1">3 (9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>other</bold>
</td><td align="left" rowspan="1" colspan="1">18 (28)</td><td align="left" rowspan="1" colspan="1">10 (32)</td><td align="left" rowspan="1" colspan="1">8 (25)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Transplantation, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Single lung-transplantation</bold>
</td><td align="left" rowspan="1" colspan="1">2 (3)</td><td align="left" rowspan="1" colspan="1">1 (3)</td><td align="left" rowspan="1" colspan="1">1 (3)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>double lung transplantation</bold>
</td><td align="left" rowspan="1" colspan="1">62 (97)</td><td align="left" rowspan="1" colspan="1">31 (97)</td><td align="left" rowspan="1" colspan="1">31 (97)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age, years</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">47 (34; 57)</td><td align="left" rowspan="1" colspan="1">52 (35.9; 57.6)</td><td align="left" rowspan="1" colspan="1">45 (33.3; 53.9)</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Immunosuppression n (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Cyclosporine</bold>
</td><td align="left" rowspan="1" colspan="1">36 (56)</td><td align="left" rowspan="1" colspan="1">19 (59)</td><td align="left" rowspan="1" colspan="1">17 (53)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Tacrolimus</bold>
</td><td align="left" rowspan="1" colspan="1">28 (44)</td><td align="left" rowspan="1" colspan="1">13 (41)</td><td align="left" rowspan="1" colspan="1">15 (47)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Baseline adherence judged by physician at inclusion, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Good</bold>
</td><td align="left" rowspan="1" colspan="1">49 (76)</td><td align="left" rowspan="1" colspan="1">27 (84)</td><td align="left" rowspan="1" colspan="1">22 (69)</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Moderate</bold>
</td><td align="left" rowspan="1" colspan="1">12 (19)</td><td align="left" rowspan="1" colspan="1">4 (13)</td><td align="left" rowspan="1" colspan="1">8 (25)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Bad</bold>
</td><td align="left" rowspan="1" colspan="1">3 (5)</td><td align="left" rowspan="1" colspan="1">1 (3)</td><td align="left" rowspan="1" colspan="1">2 (6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Adherence after 6 month) n (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Good</bold>
</td><td align="left" rowspan="1" colspan="1">47 (77)</td><td align="left" rowspan="1" colspan="1">21 (70)</td><td align="left" rowspan="1" colspan="1">26 (84)</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Moderate</bold>
</td><td align="left" rowspan="1" colspan="1">13 (21)</td><td align="left" rowspan="1" colspan="1">8 (27)</td><td align="left" rowspan="1" colspan="1">5 (16)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Bad</bold>
</td><td align="left" rowspan="1" colspan="1">1 (2)</td><td align="left" rowspan="1" colspan="1">1 (3)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Levels of immunosuppression in target range at inclusion, % (IQR)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">31 (20; 36)</td><td align="left" rowspan="1" colspan="1">31 (20.5; 36)</td><td align="left" rowspan="1" colspan="1">31 (20; 38.3)</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Absolute number of immunosuppression level within 6 months, n</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>before education</bold>
</td><td align="left" rowspan="1" colspan="1">15 (13;22)</td><td align="left" rowspan="1" colspan="1">15 (13; 22)</td><td align="left" rowspan="1" colspan="1">16 (14; 21)</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after education</bold>
</td><td align="left" rowspan="1" colspan="1">15 (13; 19)</td><td align="left" rowspan="1" colspan="1">15 (13; 20)</td><td align="left" rowspan="1" colspan="1">14 (13; 17)</td><td align="left" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Absolute number of immunosuppression levels in target range, n</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>before education</bold>
</td><td align="left" rowspan="1" colspan="1">5 (3; 7)</td><td align="left" rowspan="1" colspan="1">5 (3; 7)</td><td align="left" rowspan="1" colspan="1">5 (2; 7)</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after education</bold>
</td><td align="left" rowspan="1" colspan="1">8.5 (5; 12)</td><td align="left" rowspan="1" colspan="1">10 (5.8; 14)</td><td align="left" rowspan="1" colspan="1">7 (4.8; 9.5)</td><td align="left" rowspan="1" colspan="1">0.048</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Patient demographics and characteristics. Categorical variables were compared using a chi-square test and numeric values were shown as median with IQR, using student's t-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0090828-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090828.t003</object-id><label>Table 3</label><caption><title>End point results.</title></caption><alternatives><graphic id="pone-0090828-t003-3" xlink:href="pone.0090828.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">Time point</td><td align="left" rowspan="1" colspan="1">All patients, n&#x0200a;=&#x0200a;64</td><td align="left" rowspan="1" colspan="1">Tablet-pc group, n&#x0200a;=&#x0200a;32</td><td align="left" rowspan="1" colspan="1">Conventional group, n&#x0200a;=&#x0200a;32</td><td align="left" rowspan="1" colspan="1">Significance</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Levels of immunosuppression in target range, % (IQR)</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">55 (38; 68)</td><td align="left" rowspan="1" colspan="1">58 (50; 69.3)</td><td align="left" rowspan="1" colspan="1">48.5 (36; 67.3)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Improvement of percentage of calcineurin inhibitor trough levels in target range (Delta %) of the next 10 measurements after patient education compared to the last 10 measurements before patient education</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20 (10; 40)</td><td align="left" rowspan="1" colspan="1">30 (10; 40)</td><td align="left" rowspan="1" colspan="1">20 (7.5; 30)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Ratio of level measurements divided by recommended measurements <xref ref-type="table-fn" rid="nt102">*</xref>
</td><td align="left" rowspan="1" colspan="1">inclusion</td><td align="left" rowspan="1" colspan="1">1.11 (0.96; 1.27)</td><td align="left" rowspan="1" colspan="1">1.09 (0.90; 1.21)</td><td align="left" rowspan="1" colspan="1">1.17 (97; 1.30)</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">1.14 (1.00; 1.43)</td><td align="left" rowspan="1" colspan="1">1.24 (1.07; 1.51)</td><td align="left" rowspan="1" colspan="1">1.11 (0.96; 1.28)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Improvement of percentage of calcineurin inhibitor trough levels (Delta %) in target range 6 months after patient education compared to 6 months before patient education</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">26 (12.5; 36)</td><td align="left" rowspan="1" colspan="1">29 (17.3; 36.3)</td><td align="left" rowspan="1" colspan="1">20 (4.8; 36)</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Total time of education (first visit) (min)</td><td align="left" rowspan="1" colspan="1">inclusion</td><td align="left" rowspan="1" colspan="1">25 (21.3; 29.5)</td><td align="left" rowspan="1" colspan="1">25 (22; 28)</td><td align="left" rowspan="1" colspan="1">25 (21; 30)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Total time of answering questionnaire (first visit) (min)</td><td align="left" rowspan="1" colspan="1">inclusion</td><td align="left" rowspan="1" colspan="1">18 (14.3; 21.6)</td><td align="left" rowspan="1" colspan="1">16.5 (14; 22)</td><td align="left" rowspan="1" colspan="1">19 (16; 22)</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated glomerular filtration rate (% improvement 6 months to baseline)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4 (&#x02212;1.2; 15.1)</td><td align="left" rowspan="1" colspan="1">4 (&#x02212;1.2; 18.5)</td><td align="left" rowspan="1" colspan="1">5 (&#x02212;2.5; 13.3.)</td><td align="left" rowspan="1" colspan="1">0.37</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>*&#x0003c;1: less measurements than required, &#x0003e;1 more measurements than required.</p></fn><fn id="nt103"><label/><p>Results from pre-defined end-points. All values are shown as median with IQR (student's t-test).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0090828-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090828.t004</object-id><label>Table 4</label><caption><title>Adherence Scores.</title></caption><alternatives><graphic id="pone-0090828-t004-4" xlink:href="pone.0090828.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">Time point</td><td align="left" rowspan="1" colspan="1">All patients, n&#x0200a;=&#x0200a;64</td><td align="left" rowspan="1" colspan="1">Tablet-pc group, n&#x0200a;=&#x0200a;32</td><td align="left" rowspan="1" colspan="1">Conventional group, n&#x0200a;=&#x0200a;32</td><td align="left" rowspan="1" colspan="1">Significance</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>BAASIS questions <sup>a</sup></bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>inclusion</bold>
</td><td align="left" rowspan="1" colspan="1">4 (3; 4)</td><td align="left" rowspan="1" colspan="1">4 (3; 4)</td><td align="left" rowspan="1" colspan="1">3 (3; 4)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after 6 months</bold>
</td><td align="left" rowspan="1" colspan="1">4 (4; 4)</td><td align="left" rowspan="1" colspan="1">4 (3; 4)</td><td align="left" rowspan="1" colspan="1">4 (3; 4)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>VAS <sup>b</sup></bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>inclusion</bold>
</td><td align="left" rowspan="1" colspan="1">100 (96; 100)</td><td align="left" rowspan="1" colspan="1">100 (96.3; 100)</td><td align="left" rowspan="1" colspan="1">100 (96.3; 100)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after 6 months</bold>
</td><td align="left" rowspan="1" colspan="1">100 (100; 100)</td><td align="left" rowspan="1" colspan="1">100 (93.8; 100)</td><td align="left" rowspan="1" colspan="1">100 (100;100)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ITBS Score</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>inclusion</bold>
</td><td align="left" rowspan="1" colspan="1">14 (12; 16)</td><td align="left" rowspan="1" colspan="1">14 (12; 15)</td><td align="left" rowspan="1" colspan="1">14 (12; 16)</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after 6 months</bold>
</td><td align="left" rowspan="1" colspan="1">12 (12; 15)</td><td align="left" rowspan="1" colspan="1">13 (12; 15)</td><td align="left" rowspan="1" colspan="1">12 (12; 14)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Morisky Score</bold>
<xref ref-type="table-fn" rid="nt105">c</xref>
</td><td align="left" rowspan="1" colspan="1">
<bold>inclusion</bold>
</td><td align="left" rowspan="1" colspan="1">4 (0.29)</td><td align="left" rowspan="1" colspan="1">4 (0.25)</td><td align="left" rowspan="1" colspan="1">4 (0.34)</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after 6 months</bold>
</td><td align="left" rowspan="1" colspan="1">4 (0.22)</td><td align="left" rowspan="1" colspan="1">4 (0.18)</td><td align="left" rowspan="1" colspan="1">4 (0.25)</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Satisfaction education <sup>d</sup></bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>inclusion</bold>
</td><td align="left" rowspan="1" colspan="1">1 (0.54)</td><td align="left" rowspan="1" colspan="1">1 (0.55)</td><td align="left" rowspan="1" colspan="1">1 (0.53)</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after 6 months</bold>
</td><td align="left" rowspan="1" colspan="1">2 (0.78)</td><td align="left" rowspan="1" colspan="1">1 (0.9)</td><td align="left" rowspan="1" colspan="1">2 (0.64)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Satisfaction questionnaire</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>inclusion</bold>
</td><td align="left" rowspan="1" colspan="1">2 (0.77)</td><td align="left" rowspan="1" colspan="1">2 (0.55)</td><td align="left" rowspan="1" colspan="1">2 (0.91)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after 6 month</bold>
</td><td align="left" rowspan="1" colspan="1">2 (0.98)</td><td align="left" rowspan="1" colspan="1">2 (0.94)</td><td align="left" rowspan="1" colspan="1">2 (0.99)</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Baseline knowledge; n (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>80&#x02013;100%</bold>
</td><td align="left" rowspan="1" colspan="1">40 (63)</td><td align="left" rowspan="1" colspan="1">19 (59)</td><td align="left" rowspan="1" colspan="1">21 (66)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;80%</bold>
</td><td align="left" rowspan="1" colspan="1">24 (37)</td><td align="left" rowspan="1" colspan="1">13 (41)</td><td align="left" rowspan="1" colspan="1">11 (34)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Knowledge %</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>inclusion</bold>
</td><td align="left" rowspan="1" colspan="1">80 (71; 90)</td><td align="left" rowspan="1" colspan="1">80 (71; 90)</td><td align="left" rowspan="1" colspan="1">85 (71; 90)</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>after 6 months</bold>
</td><td align="left" rowspan="1" colspan="1">90 (81; 95)</td><td align="left" rowspan="1" colspan="1">90 (83; 95)</td><td align="left" rowspan="1" colspan="1">90 (78; 95)</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Improvement of knowledge (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7 (0; 18)</td><td align="left" rowspan="1" colspan="1">7 (0; 19)</td><td align="left" rowspan="1" colspan="1">7 (&#x02212;1; 18)</td><td align="left" rowspan="1" colspan="1">0.87</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>Results from subjective and objective adherence (BAASIS, VAS, ITBS and Morinsky scale). <sup>a</sup> Self reported adherence: 1&#x02013;4 points; 1 poor adherence, 4 very good adherence. <sup>b</sup> VAS (visual analogue scale of BAASIS questionnaire) 0 to 100; 100 very good self rated adherence.</p></fn><fn id="nt105"><label>c</label><p>Mann-Whitney-U-Test, Mean (SD); <sup>d</sup> Satisfaction, 1&#x02013;5 points (1 very good to 5 very bad); Mean (SD), Mann-Whitney-U-Test.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>Results</title><p>Sixty-four patients were enrolled between 5.8.2011 and 15.5.2012, with 32 patients being randomly assigned to each group. Three patients did not complete the study: two died and one withdrew from study. In total, 30 patients completed the study in the tablet-PC and 31 in the conventional group. Patient characteristics were similar between the groups (<xref ref-type="table" rid="pone-0090828-t002">Table 2</xref>).</p><sec id="s3a"><title>Endpoint outcomes</title><p>Primary endpoint: there was no difference between the groups in regard to levels of immunosuppression in target range after 6 months (p&#x0200a;=&#x0200a;0.27), see <xref ref-type="table" rid="pone-0090828-t003">Table 3</xref>.</p><p>Following any educational intervention, significant improvements of immunosuppression levels in target range (31% to 55%; p&#x0003c;0.001) were observed. Absolute improvement in percentage of calcineurin inhibitor trough levels (&#x00394;%) in target range in the 6 months before and after patient education showed no significant difference in a two-sided t-test between the groups. Overall, a 26% absolute improvement of CNI levels in target range was observed, with an interesting trend towards better performance in the tablet-PC group (20% vs. 29%, p&#x0200a;=&#x0200a;0.17). Secondary end-points are displayed in <xref ref-type="table" rid="pone-0090828-t003">Table 3</xref>.</p></sec><sec id="s3b"><title>Knowledge and renal function</title><p>There was no difference between groups and between time-points for renal function or knowledge (<xref ref-type="table" rid="pone-0090828-t003">Table 3</xref> and <xref ref-type="table" rid="pone-0090828-t004">4</xref>).</p></sec><sec id="s3c"><title>Self-reported and measured adherence</title><p>Results from questionnaires relating to adherence revealed no differences between inclusion and at 6 months in either group.</p><p>Three patients reported drug holidays in the preceding 4 weeks but no autonomous changes in dosage (BAASIS questionnaire). On 15 occasions prior to education, CNI intake fell outside the recommended 2-hour window, with no differences observed between groups. Following training only six patients admitted this. In ITBS, 3 patients reported that they could hardly remember taking their CNI although all knew when they should take them. Two patients reported problems correctly timed CNI dosing resulting from changes in daily schedule.</p></sec><sec id="s3d"><title>Physicians' judgment of adherence</title><p>Physicians rated most patients as adherent at inclusion (<xref ref-type="table" rid="pone-0090828-t001">Table 1</xref>). There was no significant improvement after 6 months (p&#x0200a;=&#x0200a;0.5) and no intergroup differences were observed.</p></sec><sec id="s3e"><title>Evaluation of tablet-PC usage</title><p>All patients participating in tablet-PC training successfully completed both the tutorial and the questionnaire. All patients rated training with the tablet-PC as good.</p></sec><sec id="s3f"><title>Sub-group analysis</title><p>All study participants considered themselves treatment-adherent at the time of inclusion despite poor performance in achieving therapeutic trough-levels. We, therefore, examined the influence of knowledge levels at inclusion on drug level improvement (cut-off &#x0003c;80% knowledge corresponding to median). Low knowledge levels with regard to immunosuppression were identified in 24 patients. Analysis however revealed no significant differences in improvement in these patients compared to the remainder of the cohort (29% vs. 23% respectively; p&#x0200a;=&#x0200a;0.39).</p><p>Patients rated as moderately or poorly adherent exhibited significantly lower knowledge levels (p&#x0200a;=&#x0200a;0.01). Fifteen patients judged as non-adherent at inclusion displayed smaller improvements in therapeutic CNI levels compared to patients with good adherence (23% vs. 29% respectively; p&#x0200a;=&#x0200a;0.38). Patients demonstrating poor existing knowledge and non-adherence (n&#x0200a;=&#x0200a;10) displayed no difference in drug-level improvements based on education received (p&#x0200a;=&#x0200a;0.3).</p><p>Existing level of knowledge influenced the time needed to complete the questionnaire (low knowledge: median 20 min (IQR 16&#x02013;28), good knowledge: 17 min (IQR 14&#x02013;20); p&#x0200a;=&#x0200a;0.005), but not the duration of education (low knowledge: median 26 min (IQR 23&#x02013;31), good knowledge: median 25 min (IQR 21&#x02013;28); p&#x0200a;=&#x0200a;0.3).</p></sec><sec id="s3g"><title>Hospitalization, rejection and infection during follow-up</title><p>Two patients died during follow-up, with both being in the tablet-PC group. Causes of death were lymphoma and myocardial infarction. Eight patients were hospitalized during follow-up (1 tablet-PC and 7 conventional education; p&#x0200a;=&#x0200a;0.05), due to progression in chronic rejection (n&#x0200a;=&#x0200a;2), infection (n&#x0200a;=&#x0200a;3), oesophageal biopsy (n&#x0200a;=&#x0200a;1) and vascular prosthesis (n&#x0200a;=&#x0200a;1). Seventeen patients suffered an infection, 9 of which were in the tablet-PC group (p&#x0200a;=&#x0200a;1.0). Ten patients received pulsed steroids: 6 in the tablet-PC and 4 in the conventional group (median 123 days after inclusion, p&#x0200a;=&#x0200a;0.5).</p></sec><sec id="s3h"><title>Cost-calculation</title><p>The creative time required for tablet-PC education and questionnaire compared to that for conventional education was assumed to be equal. The initial equipment outlay for tablet-PC education included an iPad (499 &#x020ac;), an Apple AirPort Express (79 &#x020ac;), the required software (Keynote for iPad, Filemaker Pro for iPad, Filemaker Server and Client, totalling 852 &#x020ac;). Short instruction in using the tablet-PC was usually required (5 min, performed by study nurse). Conventional education was provided by a study nurse (approx. 50 &#x020ac;/h employer costs) and lasted around 30 min per patient. Taken together, the cost of each educational session in tablet-PC group was 45 &#x020ac;, with conventional training costing 25 &#x020ac;. Seventy-two educational sessions were therefore required to render tablet-PC training cost-effective.</p></sec></sec><sec id="s4"><title>Discussion</title><p>In this randomized, controlled trial, tablet-PC education proved to be non-inferior in terms of improved immunosuppression-compliance compared to conventional education. Along with reduced variability in immunosuppression, significant improvements in patient knowledge were observed following further training. To our knowledge, this is the first study that studied tablet-PC education among lung-transplant recipients. Based on the described system, other educational themes after transplantation have been implemented.</p><sec id="s4a"><title>Education part</title><p>Ongoing patient education has become an established medical instrument, aiming to improve patients' knowledge about their disease and its treatment <xref rid="pone.0090828-Arsham1" ref-type="bibr">[24]</xref>, <xref rid="pone.0090828-Squyres1" ref-type="bibr">[25]</xref>. Currently, structured programmes have been developed in a variety of chronic diseases (asthma, diabetes), augmenting medical therapy <xref rid="pone.0090828-Viswanathan1" ref-type="bibr">[26]</xref>&#x02013;<xref rid="pone.0090828-Lee1" ref-type="bibr">[29]</xref>. New concepts examining the role of e-learning have emerged in recent years and promises cost effectiveness <xref rid="pone.0090828-Keulers1" ref-type="bibr">[30]</xref>&#x02013;<xref rid="pone.0090828-Sechrest1" ref-type="bibr">[32]</xref>. In common with existing studies <xref rid="pone.0090828-Keulers1" ref-type="bibr">[30]</xref>, <xref rid="pone.0090828-Evans1" ref-type="bibr">[33]</xref>&#x02013;<xref rid="pone.0090828-Miller1" ref-type="bibr">[35]</xref>, we could demonstrate non-inferiority of tablet-PC education in patients with demonstrating poor therapeutic adherence of their immunosuppression following lung-transplantation. Effectiveness of self-directed, computer-based education may be explained by increased attention that patients require whilst interacting with the device <xref rid="pone.0090828-Keulers1" ref-type="bibr">[30]</xref>. This repetition aids patients in retaining the information provided <xref rid="pone.0090828-Keulers1" ref-type="bibr">[30]</xref>, <xref rid="pone.0090828-Fox1" ref-type="bibr">[31]</xref>. Although e-education is a more standardized method than face-to-face education <xref rid="pone.0090828-Fox1" ref-type="bibr">[31]</xref>, face-to-face education offers a more individual teaching that can focus on individual problems of a given patient.</p><p>To maximize the cohort of patients capable of participating in interactive education, we chose an iPad&#x000ae;, due to its simpler handling when compared to standard laptop computers <xref rid="pone.0090828-Kho1" ref-type="bibr">[36]</xref>. Additionally, the physical design of the iPad&#x000ae; afforded straightforward decontamination (deBac-app), which was considered advantageous in a potentially infectious and simultaneously infect-susceptible patient cohort.</p></sec><sec id="s4b"><title>Cost</title><p>Computer-based, self-directed education helps reduce involvement of professional staff, which may result in economic benefits <xref rid="pone.0090828-Fox1" ref-type="bibr">[31]</xref>. A cost-calculation revealed that e-education was however more expensive than conventional education with 45 vs. 25 &#x020ac; per session in this study. Beyond 72 patients however, e-education achieves cost-effectiveness and given that our center currently follows up almost 800 patients after lung-transplantation, the tablet-PC approach offers substantial savings, particularly given the continual expansion in educational themes being added to our repertoire. Positive effects of education (better immunosuppression drug levels) lead to lengthening intervals between drug measurements and reduced laboratory costs (24 &#x020ac; per measurement) as well as postal and the cost of calls to inform patients. If the number of required trough levels could be reduced by 50%, an annual saving of 300 &#x020ac; per patient would ensue.</p></sec><sec id="s4c"><title>Immunosuppression</title><p>After multiple studies evaluating adherence, potential risk factors and the consequences of non-adherence <xref rid="pone.0090828-Bosma1" ref-type="bibr">[37]</xref>&#x02013;<xref rid="pone.0090828-KorbSavoldelli1" ref-type="bibr">[40]</xref>, this is the first study investigating two strategies to improve immunosuppression after lung-transplantation.</p></sec><sec id="s4d"><title>Aspects of patients medication adherence</title><p>Non-adherence can extend to other important aspects of patient cooperation e.g. communicating changes in health status between appointments and physical activity, which were not considered here. Stable therapeutic CNI drug levels result from patients' knowledge and discipline regarding medication consumption, correct intervals, drug metabolism and handling demanded by their inherent pharmacokinetics and &#x02013;dynamics. All patients demonstrated good fundamental knowledge at inclusion in this trial (16/20 correct answers) and appeared to follow prescribed dosing of CNI. Adherence rating by physicians correlated with knowledge test results. Whereas patients with good adherence had better knowledge, there was no correlation of knowledge and improvement of therapeutic drug levels. Consequently, good knowledge about medication alone cannot prevent from non-therapeutic drug levels. We conclude that practical advice for daily handling of immunosuppressants were highly important in achieving good compliance. Patient evaluation of the education they received illustrated this aspect clearly. Evaluation of long-term improvements on patient survival following this intervention should be evaluated in future studies.</p></sec><sec id="s4e"><title>Limitations</title><p>Larger trials testing for superiority are required to provide evidence of clinical benefit. Future studies are required to evaluate, whether education can help prevent acute and consecutively chronic lung allograft dysfunction <xref rid="pone.0090828-Husain1" ref-type="bibr">[41]</xref>.</p></sec></sec><sec id="s5"><title>Conclusion</title><p>This randomised study proves positive effects of patient education on achieving improvements in therapeutic immunosuppression levels. Tablet-PC based education proved non-inferior to personal conventional education and may help physicians to improve effectiveness of education. Due to limitations in computer literacy and handling of electronic devices, specialist input was still required. Tablet-PC education now represents an integral component in our routine management of outpatients demonstrating poor immunosuppressive treatment control. Once established, the same equipment may be used for different aspects of patient education (e.g., therapy with azithromycine or bronchial stenting), adding greatly to their cost effectiveness.</p></sec><sec sec-type="supplementary-material" id="s6"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0090828.s001"><label>Figure S1</label><caption><p>
<bold>A</bold> Patient with tablet-PC receiving education. <bold>B &#x02013; C</bold> Screenshots from included video clips. <bold>B</bold> explanation of immunosuppression levels after intake and the consequences of missing or excessive intake. <bold>C</bold> patient with excellent drug levels and adherence describes tips. <bold>D</bold> demonstration of storage of immunosuppressive drugs in a car (influence of sunlight or cold). All individuals have given written informed consent, as outlined in the PLOS consent form, to publication of their photograph.</p><p>(PNG)</p></caption><media xlink:href="pone.0090828.s001.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0090828.s002"><label>Table S1</label><caption><p>
<bold>List of tips for patients after lung-transplantation.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0090828.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0090828.s003"><label>Checklist S1</label><caption><p>
<bold>Consort checklist.</bold>
</p><p>(PDF)</p></caption><media xlink:href="pone.0090828.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0090828-Osterberg1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Osterberg</surname><given-names>L</given-names></name>, <name><surname>Blaschke</surname><given-names>T</given-names></name> (<year>2005</year>) <article-title>Adherence to medication</article-title>. <source>N Engl J Med</source>
<volume>353</volume>: <fpage>487</fpage>&#x02013;<lpage>497</lpage>.<pub-id pub-id-type="pmid">16079372</pub-id></mixed-citation></ref><ref id="pone.0090828-Trueman1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Trueman</surname><given-names>JF</given-names></name> (<year>2000</year>) <article-title>Non-adherence to medication in asthma</article-title>. <source>Prof Nurse</source>
<volume>15</volume>: <fpage>583</fpage>&#x02013;<lpage>586</lpage>.<pub-id pub-id-type="pmid">11129937</pub-id></mixed-citation></ref><ref id="pone.0090828-Ho1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Ho</surname><given-names>PM</given-names></name>, <name><surname>Magid</surname><given-names>DJ</given-names></name>, <name><surname>Masoudi</surname><given-names>FA</given-names></name>, <name><surname>McClure</surname><given-names>DL</given-names></name>, <name><surname>Rumsfeld</surname><given-names>JS</given-names></name> (<year>2006</year>) <article-title>Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease</article-title>. <source>BMC Cardiovasc Disord</source>
<volume>6</volume>: <fpage>48</fpage>.<pub-id pub-id-type="pmid">17173679</pub-id></mixed-citation></ref><ref id="pone.0090828-The1"><label>4</label><mixed-citation publication-type="other">The Boston Consulting Group Website (2003) The hidden epidemic: finding a cure for unfilled prescriptions and missed doses. Available: <ext-link ext-link-type="uri" xlink:href="http://www.bcg.com/impact_expertise/publications/files/Hidden_Epi-">http://www.bcg.com/impact_expertise/publications/files/Hidden_Epi-</ext-link> demic_Finding_Cure_Unfulfilled_Rx _Missed_Doses_Dec2003.pdf. in Accessed 2013 Apr 2.</mixed-citation></ref><ref id="pone.0090828-Delgado1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Delgado</surname><given-names>PL</given-names></name> (<year>2000</year>) <article-title>Approaches to the enhancement of patient adherence to antidepressant medication treatment</article-title>. <source>J Clin Psychiatry</source>
<volume>61</volume> Suppl 2<fpage>6</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10714617</pub-id></mixed-citation></ref><ref id="pone.0090828-DeBleser1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>De Bleser</surname><given-names>L</given-names></name>, <name><surname>Matteson</surname><given-names>M</given-names></name>, <name><surname>Dobbels</surname><given-names>F</given-names></name>, <name><surname>Russell</surname><given-names>C</given-names></name>, <name><surname>De Geest</surname><given-names>S</given-names></name> (<year>2009</year>) <article-title>Interventions to improve medication-adherence after transplantation: a systematic review</article-title>. <source>Transpl Int</source>
<volume>22</volume>: <fpage>780</fpage>&#x02013;<lpage>797</lpage>.<pub-id pub-id-type="pmid">19386076</pub-id></mixed-citation></ref><ref id="pone.0090828-Khunti1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Khunti</surname><given-names>K</given-names></name>, <name><surname>Gray</surname><given-names>LJ</given-names></name>, <name><surname>Skinner</surname><given-names>T</given-names></name>, <name><surname>Carey</surname><given-names>ME</given-names></name>, <name><surname>Realf</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care</article-title>. <source>BMJ</source>
<volume>344</volume>: <fpage>e2333</fpage>.<pub-id pub-id-type="pmid">22539172</pub-id></mixed-citation></ref><ref id="pone.0090828-Dhein1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Dhein</surname><given-names>Y</given-names></name>, <name><surname>Munks-Lederer</surname><given-names>C</given-names></name>, <name><surname>Worth</surname><given-names>H</given-names></name> (<year>2003</year>) <article-title>[Evaluation of a structured education programme for patients with COPD under outpatient conditions &#x02013; a pilot study]</article-title>. <source>Pneumologie</source>
<volume>57</volume>: <fpage>591</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">14569530</pub-id></mixed-citation></ref><ref id="pone.0090828-Gadoury1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Gadoury</surname><given-names>MA</given-names></name>, <name><surname>Schwartzman</surname><given-names>K</given-names></name>, <name><surname>Rouleau</surname><given-names>M</given-names></name>, <name><surname>Maltais</surname><given-names>F</given-names></name>, <name><surname>Julien</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Self-management reduces both short- and long-term hospitalisation in COPD</article-title>. <source>Eur Respir J</source>
<volume>26</volume>: <fpage>853</fpage>&#x02013;<lpage>857</lpage>.<pub-id pub-id-type="pmid">16264046</pub-id></mixed-citation></ref><ref id="pone.0090828-Clark1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Clark</surname><given-names>NM</given-names></name>, <name><surname>Feldman</surname><given-names>CH</given-names></name>, <name><surname>Evans</surname><given-names>D</given-names></name>, <name><surname>Millman</surname><given-names>EJ</given-names></name>, <name><surname>Wailewski</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>1981</year>) <article-title>The effectiveness of education for family management of asthma in children: a preliminary report</article-title>. <source>Health Educ Q</source>
<volume>8</volume>: <fpage>166</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">7298348</pub-id></mixed-citation></ref><ref id="pone.0090828-Best1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Best</surname><given-names>NG</given-names></name>, <name><surname>Trull</surname><given-names>AK</given-names></name>, <name><surname>Tan</surname><given-names>KK</given-names></name>, <name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>, <name><surname>Cary</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Pharmacodynamics of cyclosporine in heart and heart-lung transplant recipients. I: Blood cyclosporine concentrations and other risk factors for cardiac allograft rejection</article-title>. <source>Transplantation</source>
<volume>62</volume>: <fpage>1429</fpage>&#x02013;<lpage>1435</lpage>.<pub-id pub-id-type="pmid">8958268</pub-id></mixed-citation></ref><ref id="pone.0090828-PollockBarziv1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Pollock-Barziv</surname><given-names>SM</given-names></name>, <name><surname>Finkelstein</surname><given-names>Y</given-names></name>, <name><surname>Manlhiot</surname><given-names>C</given-names></name>, <name><surname>Dipchand</surname><given-names>AI</given-names></name>, <name><surname>Hebert</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children</article-title>. <source>Pediatr Transplant</source>
<volume>14</volume>: <fpage>968</fpage>&#x02013;<lpage>975</lpage>.<pub-id pub-id-type="pmid">21040278</pub-id></mixed-citation></ref><ref id="pone.0090828-Dew1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Dew</surname><given-names>MA</given-names></name>, <name><surname>Dimartini</surname><given-names>AF</given-names></name>, <name><surname>De Vito Dabbs</surname><given-names>A</given-names></name>, <name><surname>Zomak</surname><given-names>R</given-names></name>, <name><surname>De Geest</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Adherence to the medical regimen during the first two years after lung transplantation</article-title>. <source>Transplantation</source>
<volume>85</volume>: <fpage>193</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">18212623</pub-id></mixed-citation></ref><ref id="pone.0090828-Dharancy1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Dharancy</surname><given-names>S</given-names></name>, <name><surname>Giral</surname><given-names>M</given-names></name>, <name><surname>Tetaz</surname><given-names>R</given-names></name>, <name><surname>Fatras</surname><given-names>M</given-names></name>, <name><surname>Dubel</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT</article-title>. <source>Clin Transplant</source>
<volume>26</volume>: <fpage>E293</fpage>&#x02013;<lpage>299</lpage>.<pub-id pub-id-type="pmid">22686953</pub-id></mixed-citation></ref><ref id="pone.0090828-Donaghy1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Donaghy</surname><given-names>D</given-names></name> (<year>1995</year>) <article-title>The asthma specialist and patient education</article-title>. <source>Prof Nurse</source>
<volume>11</volume>: <fpage>160</fpage>&#x02013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">8552685</pub-id></mixed-citation></ref><ref id="pone.0090828-Miners1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Miners</surname><given-names>A</given-names></name>, <name><surname>Harris</surname><given-names>J</given-names></name>, <name><surname>Felix</surname><given-names>L</given-names></name>, <name><surname>Murray</surname><given-names>E</given-names></name>, <name><surname>Michie</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>An economic evaluation of adaptive e-learning devices to promote weight loss via dietary change for people with obesity</article-title>. <source>BMC Health Serv Res</source>
<volume>12</volume>: <fpage>190</fpage>.<pub-id pub-id-type="pmid">22769737</pub-id></mixed-citation></ref><ref id="pone.0090828-Gottlieb1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Gottlieb</surname><given-names>J</given-names></name>, <name><surname>Mattner</surname><given-names>F</given-names></name>, <name><surname>Weissbrodt</surname><given-names>H</given-names></name>, <name><surname>Dierich</surname><given-names>M</given-names></name>, <name><surname>Fuehner</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis</article-title>. <source>Respir Med</source>
<volume>103</volume>: <fpage>743</fpage>&#x02013;<lpage>749</lpage>.<pub-id pub-id-type="pmid">19117741</pub-id></mixed-citation></ref><ref id="pone.0090828-Walsh1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Walsh</surname><given-names>JC</given-names></name>, <name><surname>Mandalia</surname><given-names>S</given-names></name>, <name><surname>Gazzard</surname><given-names>BG</given-names></name> (<year>2002</year>) <article-title>Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome</article-title>. <source>AIDS</source>
<volume>16</volume>: <fpage>269</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">11807312</pub-id></mixed-citation></ref><ref id="pone.0090828-Terebelo1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Terebelo</surname><given-names>S</given-names></name>, <name><surname>Markell</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Preferential adherence to immunosuppressive over nonimmunosuppressive medications in kidney transplant recipients</article-title>. <source>Transplant Proc</source>
<volume>42</volume>: <fpage>3578</fpage>&#x02013;<lpage>3585</lpage>.<pub-id pub-id-type="pmid">21094819</pub-id></mixed-citation></ref><ref id="pone.0090828-Lennerling1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Lennerling</surname><given-names>A</given-names></name>, <name><surname>Forsberg</surname><given-names>A</given-names></name> (<year>2012</year>) <article-title>Self-reported non-adherence and beliefs about medication in a Swedish kidney transplant population</article-title>. <source>Open Nurs J</source>
<volume>6</volume>: <fpage>41</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">22509233</pub-id></mixed-citation></ref><ref id="pone.0090828-Chisholm1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Chisholm</surname><given-names>MA</given-names></name>, <name><surname>Lance</surname><given-names>CE</given-names></name>, <name><surname>Williamson</surname><given-names>GM</given-names></name>, <name><surname>Mulloy</surname><given-names>LL</given-names></name> (<year>2005</year>) <article-title>Development and validation of an immunosuppressant therapy adherence barrier instrument</article-title>. <source>Nephrol Dial Transplant</source>
<volume>20</volume>: <fpage>181</fpage>&#x02013;<lpage>188</lpage>.<pub-id pub-id-type="pmid">15572384</pub-id></mixed-citation></ref><ref id="pone.0090828-Morisky1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Morisky</surname><given-names>DE</given-names></name>, <name><surname>Green</surname><given-names>LW</given-names></name>, <name><surname>Levine</surname><given-names>DM</given-names></name> (<year>1986</year>) <article-title>Concurrent and predictive validity of a self-reported measure of medication adherence</article-title>. <source>Med Care</source>
<volume>24</volume>: <fpage>67</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">3945130</pub-id></mixed-citation></ref><ref id="pone.0090828-DelTacca1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Del Tacca</surname><given-names>M</given-names></name> (<year>2004</year>) <article-title>Prospects for personalized immunosuppression: pharmacologic tools &#x02013; a review</article-title>. <source>Transplant Proc</source>
<volume>36</volume>: <fpage>687</fpage>&#x02013;<lpage>689</lpage>.<pub-id pub-id-type="pmid">15110631</pub-id></mixed-citation></ref><ref id="pone.0090828-Arsham1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Arsham</surname><given-names>GM</given-names></name>, <name><surname>Bartlett</surname><given-names>EE</given-names></name>, <name><surname>Cohen</surname><given-names>EJ</given-names></name>, <name><surname>Squyres</surname><given-names>WD</given-names></name>, <name><surname>DuVal</surname><given-names>MK</given-names></name> (<year>1979</year>) <article-title>Symposium: Patient/health education: training for what?</article-title>
<source>Annu Conf Res Med Educ</source>
<volume>18</volume>: <fpage>407</fpage>&#x02013;<lpage>416</lpage>.<pub-id pub-id-type="pmid">496349</pub-id></mixed-citation></ref><ref id="pone.0090828-Squyres1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Squyres</surname><given-names>WD</given-names></name> (<year>1983</year>) <article-title>Challenges in health education practice</article-title>. <source>J Biocommun</source>
<volume>10</volume>: <fpage>4</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0090828-Viswanathan1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Viswanathan</surname><given-names>M</given-names></name>, <name><surname>Golin</surname><given-names>CE</given-names></name>, <name><surname>Jones</surname><given-names>CD</given-names></name>, <name><surname>Ashok</surname><given-names>M</given-names></name>, <name><surname>Blalock</surname><given-names>SJ</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review</article-title>. <source>Ann Intern Med</source>
<volume>157</volume>: <fpage>785</fpage>&#x02013;<lpage>795</lpage>.<pub-id pub-id-type="pmid">22964778</pub-id></mixed-citation></ref><ref id="pone.0090828-Deakin1"><label>27</label><mixed-citation publication-type="other">Deakin T, McShane CE, Cade JE, Williams RD (2005) Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev: CD003417.</mixed-citation></ref><ref id="pone.0090828-Duke1"><label>28</label><mixed-citation publication-type="other">Duke SA, Colagiuri S, Colagiuri R (2009) Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev: CD005268.</mixed-citation></ref><ref id="pone.0090828-Lee1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Lee</surname><given-names>TI</given-names></name>, <name><surname>Yeh</surname><given-names>YT</given-names></name>, <name><surname>Liu</surname><given-names>CT</given-names></name>, <name><surname>Chen</surname><given-names>PL</given-names></name> (<year>2007</year>) <article-title>Development and evaluation of a patient-oriented education system for diabetes management</article-title>. <source>Int J Med Inform</source>
<volume>76</volume>: <fpage>655</fpage>&#x02013;<lpage>663</lpage>.<pub-id pub-id-type="pmid">16815741</pub-id></mixed-citation></ref><ref id="pone.0090828-Keulers1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Keulers</surname><given-names>BJ</given-names></name>, <name><surname>Welters</surname><given-names>CF</given-names></name>, <name><surname>Spauwen</surname><given-names>PH</given-names></name>, <name><surname>Houpt</surname><given-names>P</given-names></name> (<year>2007</year>) <article-title>Can face-to-face patient education be replaced by computer-based patient education? A randomised trial</article-title>. <source>Patient Educ Couns</source>
<volume>67</volume>: <fpage>176</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">17448621</pub-id></mixed-citation></ref><ref id="pone.0090828-Fox1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Fox</surname><given-names>MP</given-names></name> (<year>2009</year>) <article-title>A systematic review of the literature reporting on studies that examined the impact of interactive, computer-based patient education programs</article-title>. <source>Patient Educ Couns</source>
<volume>77</volume>: <fpage>6</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">19345550</pub-id></mixed-citation></ref><ref id="pone.0090828-Sechrest1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Sechrest</surname><given-names>RC</given-names></name>, <name><surname>Henry</surname><given-names>DJ</given-names></name> (<year>1996</year>) <article-title>Computer-based patient education: observations on effective communication in the clinical setting</article-title>. <source>J Biocommun</source>
<volume>23</volume>: <fpage>8</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="pone.0090828-Evans1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Evans</surname><given-names>AE</given-names></name>, <name><surname>Edmundson-Drane</surname><given-names>EW</given-names></name>, <name><surname>Harris</surname><given-names>KK</given-names></name> (<year>2000</year>) <article-title>Computer-assisted instruction: an effective instructional method for HIV prevention education?</article-title>
<source>J Adolesc Health</source>
<volume>26</volume>: <fpage>244</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">10734271</pub-id></mixed-citation></ref><ref id="pone.0090828-Wydra1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Wydra</surname><given-names>EW</given-names></name> (<year>2001</year>) <article-title>The effectiveness of a self-care management interactive multimedia module</article-title>. <source>Oncol Nurs Forum</source>
<volume>28</volume>: <fpage>1399</fpage>&#x02013;<lpage>1407</lpage>.<pub-id pub-id-type="pmid">11683310</pub-id></mixed-citation></ref><ref id="pone.0090828-Miller1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Miller</surname><given-names>DP</given-names><suffix>Jr</suffix></name>, <name><surname>Kimberly</surname><given-names>JR</given-names><suffix>Jr</suffix></name>, <name><surname>Case</surname><given-names>LD</given-names></name>, <name><surname>Wofford</surname><given-names>JL</given-names></name> (<year>2005</year>) <article-title>Using a computer to teach patients about fecal occult blood screening. A randomized trial</article-title>. <source>J Gen Intern Med</source>
<volume>20</volume>: <fpage>984</fpage>&#x02013;<lpage>988</lpage>.<pub-id pub-id-type="pmid">16307621</pub-id></mixed-citation></ref><ref id="pone.0090828-Kho1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Kho</surname><given-names>A</given-names></name>, <name><surname>Henderson</surname><given-names>LE</given-names></name>, <name><surname>Dressler</surname><given-names>DD</given-names></name>, <name><surname>Kripalani</surname><given-names>S</given-names></name> (<year>2006</year>) <article-title>Use of handheld computers in medical education. A systematic review</article-title>. <source>J Gen Intern Med</source>
<volume>21</volume>: <fpage>531</fpage>&#x02013;<lpage>537</lpage>.<pub-id pub-id-type="pmid">16704405</pub-id></mixed-citation></ref><ref id="pone.0090828-Bosma1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Bosma</surname><given-names>OH</given-names></name>, <name><surname>Vermeulen</surname><given-names>KM</given-names></name>, <name><surname>Verschuuren</surname><given-names>EA</given-names></name>, <name><surname>Erasmus</surname><given-names>ME</given-names></name>, <name><surname>van der Bij</surname><given-names>W</given-names></name> (<year>2011</year>) <article-title>Adherence to immunosuppression in adult lung transplant recipients: prevalence and risk factors</article-title>. <source>J Heart Lung Transplant</source>
<volume>30</volume>: <fpage>1275</fpage>&#x02013;<lpage>1280</lpage>.<pub-id pub-id-type="pmid">21724418</pub-id></mixed-citation></ref><ref id="pone.0090828-DeVitoDabbs1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>DeVito Dabbs</surname><given-names>A</given-names></name>, <name><surname>Dew</surname><given-names>MA</given-names></name>, <name><surname>Myers</surname><given-names>B</given-names></name>, <name><surname>Begey</surname><given-names>A</given-names></name>, <name><surname>Hawkins</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Evaluation of a hand-held, computer-based intervention to promote early self-care behaviors after lung transplant</article-title>. <source>Clin Transplant</source>
<volume>23</volume>: <fpage>537</fpage>&#x02013;<lpage>545</lpage>.<pub-id pub-id-type="pmid">19473201</pub-id></mixed-citation></ref><ref id="pone.0090828-Ivarsson1"><label>39</label><mixed-citation publication-type="other">Ivarsson B, Ekmehag B, Sjoberg T (2012) Patients experiences of information and support during the first six months after heart or lung transplantation. Eur J Cardiovasc Nurs.</mixed-citation></ref><ref id="pone.0090828-KorbSavoldelli1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Korb-Savoldelli</surname><given-names>V</given-names></name>, <name><surname>Sabatier</surname><given-names>B</given-names></name>, <name><surname>Gillaizeau</surname><given-names>F</given-names></name>, <name><surname>Guillemain</surname><given-names>R</given-names></name>, <name><surname>Prognon</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Non-adherence with drug treatment after heart or lung transplantation in adults: a systematic review</article-title>. <source>Patient Educ Couns</source>
<volume>81</volume>: <fpage>148</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">20627643</pub-id></mixed-citation></ref><ref id="pone.0090828-Husain1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Husain</surname><given-names>AN</given-names></name>, <name><surname>Siddiqui</surname><given-names>MT</given-names></name>, <name><surname>Holmes</surname><given-names>EW</given-names></name>, <name><surname>Chandrasekhar</surname><given-names>AJ</given-names></name>, <name><surname>McCabe</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Analysis of risk factors for the development of bronchiolitis obliterans syndrome</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>159</volume>: <fpage>829</fpage>&#x02013;<lpage>833</lpage>.<pub-id pub-id-type="pmid">10051258</pub-id></mixed-citation></ref></ref-list></back></article>